Alpine’s pipeline. (Alpine Graphic)
Alpine Immune Sciences will move a potential treatment for immune conditions into human testing and support its ongoing trials for cancer thanks to around $91 million in new funding.
The publicly traded biotech is raising the funds through a private placement, announced Wednesday, offering securities to a select group of investors. The private offering, led by Seattle-based Frazier Healthcare Partners, will close on Friday.
The funding will fuel Alpine’s program developing ALPN-303, designed to treat lupus and other inflammatory diseases. The company expects to initiate a phase 1 study for the agent by this winter.
The funding will also support clinical studies of ALPN-202, which is designed to prompt an immune response against tumor cells. The company presented data from its phase 1 study on ALPN-202 this year, suggesting that the agent is well-tolerated and appeared to have a clinical benefit in a small group of cancer patients.
Alpine is also collaborating with Merck to test the pharma giant’s blockbuster cancer immunotherapy drug Keytruda in combination with ALPN-202 in a separate phase 1 trial.
James Topper, managing general partner of Frazier Healthcare Partners. (Frazier Photo)
“As a long-term backer of Alpine, we are impressed by the company’s progress and …read more
NASA Chooses Spacex To Launch A Self Propelled Space Station To The Moon